Biozen Recognized as Finalist for the ACC 2026 Innovation Pitch Challenge

Biozen Selected as a Finalist in the ACC 2026 Innovation Pitch Challenge

Biozen, LLC has recently announced its inclusion as a finalist in the prestigious American College of Cardiology (ACC) Future Hub Innovation Pitch Challenge. The event, set to take place from March 28 to March 30, 2026, at the Ernest N. Morial Convention Center in New Orleans, aims to highlight groundbreaking noninvasive technologies that are set to reshape the field of cardiovascular care.

Out of a competitive pool of global applicants, Biozen stands out as one of only four companies chosen to present its innovative technology to a distinguished panel of industry experts at the ACC Scientific Sessions. This honor underscores the importance of the advancements Biozen is bringing to the table, particularly in the realm of blood pressure measurement.

Overview of Biozen's Innovative Technology

At the heart of Biozen’s advancements is its ultra-compact BP1000 device. This revolutionary technology allows for absolute blood pressure measurements without the traditional cuffs or the requirement for calibration—addressing a critical long-standing issue within the field of noninvasive blood pressure monitoring.

Leveraging a mix of proprietary pressure and optical sensing technologies, along with sophisticated physiologically-informed algorithms, Biozen’s device measures blood pressure directly from the digital artery located at the fingertip. This process captures the arterial pressure the moment it occurs, resulting in a highly accurate blood pressure reading. Such precision is established in accordance with clinical standards, providing healthcare providers with reliable data for patient care.

Dikran Tourian, the CEO of Biozen, expressed the team's excitement regarding this recognition, stating, "Being selected as a finalist in the ACC Innovation Pitch Challenge is a significant milestone for our team. Our goal is to make clinically dependable blood pressure measurement accessible without the limitations of conventional cuffs. We are eager to demonstrate how our technology can facilitate this on a larger scale."

The Importance of the ACC Scientific Sessions

The ACC brings together a vast array of professionals including clinicians, researchers, innovators, and investors who are driving advancements in cardiovascular medicine. Omer Inan, PhD, Chief Scientific Officer at Biozen, also emphasized the value of this event, indicating the opportunity to present their innovative approach to blood pressure measurement. The forthcoming participation in the Innovation Pitch Challenge will not only showcase Biozen’s technology but will also feature prospective clinical validation data that adheres to the ISO 81060-22018 validation protocol.

About Biozen

Biozen, LLC is a digital health company based in Oklahoma City, Oklahoma, with its research and development operations located in Atlanta, Georgia. The company focuses on a cuffless blood pressure monitoring platform designed to combine advanced biosensor technology with proprietary algorithms. This innovation is safeguarded by over 65 granted patents in the U.S. and internationally, reinforcing Biozen's commitment to delivering precise, calibration-free blood pressure readings straight from the fingertip.

It is important to note that the Biozen BP Sensor and BP1000 are still investigational devices and are not yet cleared for commercial distribution by the U.S. Food and Drug Administration (FDA).

For further details about Biozen and its cutting-edge technology, please visit biozen.com.

In conclusion, Biozen’s recognition as a finalist in the ACC Innovation Pitch Challenge demonstrates the company's dedication to revolutionizing cardiovascular monitoring. This innovative approach not only promises to enhance accuracy but also aims to broaden accessibility for patients around the world. The anticipation for the upcoming presentations at the ACC is palpable, and the potential implications of such technology could set a new standard in the realm of cardiovascular care.